These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24728030)

  • 1. Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica.
    Naranjo A; López R; García-Magallón B; Cáceres L; Francisco F; Jiménez-Palop M; Ojeda-Bruno S
    Rheumatol Int; 2014 Oct; 34(10):1459-63. PubMed ID: 24728030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Permanent Discontinuation of Glucocorticoids in Polymyalgia Rheumatica Is Uncommon but May Be Enhanced by Amino Bisphosphonates.
    Giollo A; Rossini M; Bettili F; Ghellere F; Fracassi E; Idolazzi L; Gatti D; Viapiana O
    J Rheumatol; 2019 Mar; 46(3):318-322. PubMed ID: 30385701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid-Induced Osteoporosis Prevention in Polymyalgia Rheumatica Patients.
    Swami T; Molloy C
    Ir Med J; 2020 Mar; 113(3):36. PubMed ID: 32815678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoid-Induced Osteoporosis.
    Buckley L; Humphrey MB
    N Engl J Med; 2018 Dec; 379(26):2547-2556. PubMed ID: 30586507
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study.
    Rossini M; Viapiana O; Vitiello M; Malavolta N; La Montagna G; Maddali Bongi S; Di Munno O; Nuti R; Manzini CU; Ferri C; Bogliolo L; Mathieu A; Cantatore F; Del Puente A; Muratore M; Grassi W; Frediani B; Saviola G; Delvino P; Mirone L; Ferraccioli G; Tripi G; Piazza I; Gatti D
    Reumatismo; 2017 May; 69(1):30-39. PubMed ID: 28535619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids: are we offering the best care?
    Sapkota S; Baig S; Hess T; O'Connell AM; Menk J; Shyne M; Fazeli P; Ensrud K; Shmagel A
    Lupus; 2020 Mar; 29(3):263-272. PubMed ID: 31996109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survey of steroid-related osteoporosis diagnosis, prevention and treatment practices of pediatric rheumatologists in North America.
    Soybilgic A; Tesher M; Wagner-Weiner L; Onel KB
    Pediatr Rheumatol Online J; 2014; 12():24. PubMed ID: 25053923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback: a randomised controlled trial.
    Klop C; de Vries F; Vinks T; Kooij MJ; van Staa TP; Bijlsma JW; Egberts AC; Bouvy ML
    Osteoporos Int; 2014 Jan; 25(1):385-92. PubMed ID: 24221450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fracture Risk and Its Prevention Patterns in Korean Patients with Polymyalgia Rheumatica: a Retrospective Cohort Study.
    Nam B; Sung YK; Choi CB; Kim TH; Jun JB; Bae SC; Yoo DH; Cho SK
    J Korean Med Sci; 2021 Oct; 36(41):e263. PubMed ID: 34697929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
    Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
    Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of bisphosphonates and dual-energy X-ray absorptiometry scans in the prevention and treatment of glucocorticoid-induced osteoporosis in rheumatology.
    Wall E; Walker-Bone K
    QJM; 2008 Apr; 101(4):317-23. PubMed ID: 18270228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trabecular Bone Score Is a Useful Parameter for the Prediction of Vertebral Fractures in Patients With Polymyalgia Rheumatica.
    Kim HA; Lee HY; Jung JY; Suh CH; Chung YS; Choi YJ
    J Clin Densitom; 2020; 23(3):373-380. PubMed ID: 31174962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
    Cruse LM; Valeriano J; Vasey FB; Carter JD
    J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoid-induced osteoporosis.
    Hahn BH; Mazzaferri EL
    Hosp Pract (1995); 1995 Aug; 30(8):45-9, 52-3; discussion 53-6. PubMed ID: 7635911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy.
    Liu RH; Albrecht J; Werth VP
    Arch Dermatol; 2006 Jan; 142(1):37-41. PubMed ID: 16415384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
    Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
    Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?
    van der Goes MC; Jacobs JW; Jurgens MS; Bakker MF; van der Veen MJ; van der Werf JH; Welsing PM; Bijlsma JW
    Osteoporos Int; 2013 Apr; 24(4):1429-36. PubMed ID: 23011680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.